NSCLC

News

Amgen nabs speedy approval for first-ever KRAS drug sotorasi...

After decades of mostly unsuccessful R&D, Amgen has claimed the first ever regulatory approval for a drug that inhibits KRAS – a cancer target that for a long time was all-but written o

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen claims FDA okay for would-be Tagrisso rival Rybrevan...

Johnson & Johnson's Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant as a treatment for EGFR-mutated non-small cell lung cancer (NSCLC).

News

Tagrisso trial halted early after ‘overwhelming’ efficacy

A phase III trial for AstraZeneca’s lung cancer drug Tagrisso (osimertinib) will be unblinded early after strong results.

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

Keytruda approved for combination lung cancer therapy

The US Food and Drug Administration (FDA) has approved Merck & Co’s Keytruda plus chemotherapy as a first-line treatment for non-small cell lung cancer (NSCLC).

News

AZ’s Tagrisso wins new NSCLC first-line approval in Europe

AstraZeneca has widened the licence for its cancer drug Tagrisso (osimertinib) in Europe after regulators gave it the green-light for first-line use against additional types of non-small ce

News

NICE recommends Pfizer’s Xalkori in rare lung cancer

NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).

Amgen nabs speedy approval for first-ever KRAS drug sotorasi...

Janssen claims FDA okay for would-be Tagrisso rival Rybrevan...

Tagrisso trial halted early after ‘overwhelming’ efficacy

Keytruda approved for combination lung cancer therapy

AZ’s Tagrisso wins new NSCLC first-line approval in Europe

NICE recommends Pfizer’s Xalkori in rare lung cancer

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

NSCLC

Editor's Picks